Pittenger & Anderson Inc. Lowers Stock Holdings in Becton, Dickinson and Company $BDX

Pittenger & Anderson Inc. decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 7.0% during the second quarter, Holdings Channel reports. The institutional investor owned 2,312 shares of the medical instruments supplier’s stock after selling 175 shares during the period. Pittenger & Anderson Inc.’s holdings in Becton, Dickinson and Company were worth $398,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Saudi Central Bank purchased a new position in shares of Becton, Dickinson and Company during the 1st quarter valued at $26,000. Smallwood Wealth Investment Management LLC purchased a new position in shares of Becton, Dickinson and Company during the 1st quarter valued at $27,000. Alpine Bank Wealth Management purchased a new position in shares of Becton, Dickinson and Company during the 1st quarter valued at $29,000. Cornerstone Planning Group LLC lifted its stake in shares of Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 99 shares in the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA purchased a new position in shares of Becton, Dickinson and Company during the 1st quarter valued at $31,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director directly owned 22,226 shares in the company, valued at $4,167,375. The trade was a 3.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last 90 days, insiders have sold 1,838 shares of company stock valued at $348,392. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $188.97 on Wednesday. The company’s 50-day moving average price is $190.46 and its 200-day moving average price is $184.29. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The company has a market cap of $54.16 billion, a PE ratio of 33.99, a price-to-earnings-growth ratio of 1.49 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.32 billion for the quarter. On average, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on BDX shares. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Argus lifted their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Piper Sandler reiterated a “neutral” rating and issued a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Morgan Stanley lifted their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and issued a $211.00 price target on shares of Becton, Dickinson and Company in a report on Thursday, October 16th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $205.40.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.